Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Myeloid Leukemia
- Essential Thrombocythemia
- Myelodysplastic Syndrome
- Myelodysplastic/Myeloproliferative Neoplasm
- Myeloproliferative Neoplasm
- Myeloproliferative Neoplasm, Unclassifiable
- Polycythemia Vera
- Primary Myelofibrosis
- Secondary Myelofibrosis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
OUTLINE: Patients receive decitabine intravenously (IV) once daily (QD) over 1 hour on days 1-10, and either ruxolitinib orally (PO) twice daily (BID) or fedratinib PO daily on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicit...
OUTLINE: Patients receive decitabine intravenously (IV) once daily (QD) over 1 hour on days 1-10, and either ruxolitinib orally (PO) twice daily (BID) or fedratinib PO daily on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for up to 5 years.
Tracking Information
- NCT #
- NCT04282187
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Anna Halpern Fred Hutch/University of Washington Cancer Consortium
Get Well Soon